HLS Therapeutics (TSE:HLS) Posts Quarterly Earnings Results

HLS Therapeutics (TSE:HLS) announced its quarterly earnings results on Friday. The company reported C($0.10) EPS for the quarter, FiscalAI reports. The firm had revenue of C$17.88 million for the quarter. HLS Therapeutics had a negative net margin of 22.34% and a negative return on equity of 19.40%.

Here are the key takeaways from HLS Therapeutics’ conference call:

• HLS reported Q1 revenue of CAD 12.9 million, up 2% year over year, led by 15% growth in Vascepa net sales. Management said the product is benefiting from commercial changes made in 2025 and expects double-digit growth for Vascepa in 2026.
• NILEMDO’s launch is off to a strong start, with nearly CAD 250,000 shipped in just over a month and repeated wholesale reorders indicating early demand. Canada Life and Sun Life have already added the drug with full coverage and no restrictions, covering about 40% of privately insured lives.
• The company reaffirmed 2026 guidance for revenue of CAD 56 million-CAD 60 million and adjusted EBITDA of CAD 18.5 million-CAD 21 million. Management said launch-related spending will be concentrated in the first half of the year, with margins expected to improve as NILEMDO revenue ramps.
• Cash generation and deleveraging improved materially, with cash from operations up 80% year over year and net debt down to $31.9 million, a 52% reduction over two years. The company also highlighted room for future share buybacks and additional business development activity.
• Management sees two major growth catalysts ahead: public reimbursement for NILEMDO in 2027 and a planned launch of NEXLETOL in the first half of 2027. They said the combined cardiovascular franchise could potentially more than double the size of the company over time.

HLS Therapeutics Stock Down 1.7%

Shares of HLS Therapeutics stock traded down C$0.08 during trading on Friday, hitting C$4.59. 700 shares of the stock traded hands, compared to its average volume of 8,485. The firm has a market cap of C$143.55 million, a P/E ratio of -11.77 and a beta of 0.39. The company has a current ratio of 1.11, a quick ratio of 1.01 and a debt-to-equity ratio of 80.79. HLS Therapeutics has a 52-week low of C$4.22 and a 52-week high of C$5.77. The stock’s fifty day simple moving average is C$4.50 and its 200 day simple moving average is C$4.71.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.